Delayed Recovery and Increased Severity of Paclitaxel-Induced Peripheral Neuropathy in Patients With Diabetes

Barrio, Pilar de la Morena; Conesa, M.A. Vicente; González-Billalabeitia, Enrique; Urrego, Edgar; García-Garré, Elisa; García‐Martínez, Elena; Poves, Marta Zafra; Vicente, Vicente; Peña, Francisco Ayala de la

doi:10.6004/jnccn.2015.0057

Cited by 27 publications

(43 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…De la Morena et al found similar findings in patients with breast cancer treated with paclitaxel every week. They demonstrated that preexisting diabetes was associated with long-lasting significant neuropathy [20]. As well as with Taxol, several authors have described that diabetic patients are more vulnerable to develop OXLIN.…”

Section: Discussionmentioning

confidence: 99%

Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy

et al. 2017

View full text Add to dashboard Cite

BackgroundOxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around 60–80% of the patients, and 15% of them develop severe neuropathy. The pathophysiology of oxaliplatin neurotoxicity remains unclear. SCN9A is a gene codifying for a subtype sodium channel (type IX, subunit α) and mutations in this gene are involved in neuropathic perception. In this study we investigated whether SCN9A genetic variants were associated with risk of neurotoxicity in patients diagnosed of cancer on treatment with oxaliplatin.MethodsBlood samples from 94 patients diagnosed of digestive cancer that had received oxaliplatin in adjuvant or metastatic setting were obtained from three hospitals in Madrid. These patients were classified into two groups: “cases” developed oxaliplatin-induced grade 3–4 neuropathy (n = 48), and “controls” (n = 46) had no neuropathy or grade 1. The neuropathy was evaluated by an expert neurologist and included a clinical examination and classification according to validated neurological scales: National Cancer Institute Common Toxicity Criteria (NCI-CTC), Oxaliplatin-Specific Neurotoxicity Scale (OSNS) and Total Neuropathy score (TNS). Genotyping was performed for 3 SCN9A missense polymorphisms: rs6746030 (R1150W), rs74401238 (R1110Q) and rs41268673 (P610T), and associations between genotypes and neuropathy were evaluated.ResultsWe found that SCN9A rs6746030 was associated with protection for severe neuropathy (OR = 0.39, 95% CI = 0.16–0.96; p = 0.041). Multivariate analysis adjusting for diabetes provided similar results (p = 0.036). No significant differences in neuropathy risk were detected for rs74401238 and rs41268673.Conclusion SCN9A rs6746030 was associated with protection for severe oxaliplatin-induced peripheral neuropathy. The validation of this exploratory study is ongoing in an independent series.

show abstract

Section: Discussionmentioning

confidence: 99%

Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In one case-control study of breast cancer patients treated with weekly paclitaxel, diabetes mellitus (DM) was the only independent factor found to predict for delayed recovery. After 2 years, 68.7% of patients with DM (vs 29.2% of women without DM) still experienced CIPN, which was functionally significant (grade 2-3) in 18.2% [18]. …”

Section: Clinical Features Of Cipn Associated With Taxanes and Plmentioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy: Current status and progress

Brewer

Morrison

Dolan

et al. 2016

Gynecologic Oncology

211

205

View full text Add to dashboard Cite

As there are increasing numbers of cancer survivors, more attention is being paid to the long term unwanted effects patients may experience as a result of their treatment and the impact these side effects can have on their quality of life. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common long-term toxicities from chemotherapy. In this review we will briefly review the clinical presentation, evaluation and management of chemotherapy-induced peripheral neuropathy, with a focus on CIPN related to platinum and taxane agents. We will then discuss current clinical models of peripheral neuropathy and ongoing research to better understand CIPN and develop potential treatment options.

show abstract

“…5 Taxane-induced peripheral neuropathy (TIPN) usually appears during the 4 to 6 first weeks of treatment 6 with a frequency estimated at 14% with docetaxel and 60% with paclitaxel. 7 Age, 8 body mass index (BMI), 9 taxane type, 10 diabetes, 11 cardiovascular risk factors 10 are described as risk factors.…”

mentioning

confidence: 99%

Persistent taxane‐induced neuropathy in elderly patients treated for localized breast cancer

et al. 2020

View full text Add to dashboard Cite

Breast cancer is the most common cancer among women. Localized breast cancer treatments involve taxanes which are often responsible for acute peripheral neuropathy. The persistence of taxane‐induced peripheral neuropathy (TIPN) is scarcely described among elderly women. A monocenter historical cohort study including all women over 65 years of age treated between 2001 and 2016 with a taxane‐based chemotherapy for localized breast cancer was carried out at the Paul Strauss Regional Comprehensive Cancer Center. All cases included were followed up for at least 2 years, deaths from causes unrelated to TIPN were excluded. We report on the frequency and risk factors and establish a prognostic score of persistent Common Terminology Criteria for Adverse Events (CTCAE) grade 2 and 3 TIPN. Among the 302 included patients, 21% and 9% developed persistent TIPN of grade 2 and 3, respectively. Two patients died from complications of grade 3 TIPN. Risk factors of persistent grade 2 and higher neuropathy included age (P < .0001), body mass index (P < .0001), and diabetes (P = .0093). Persistent TIPN was more frequent with paclitaxel than docetaxel (OR = 5.43; P < .0001). Patients presenting all four major risk factors had a 97.2% probability of developing long‐term symptoms against 1.2% for patients showing no risk factor. We therefore identified 3 prognostic groups. TIPN is a frequent and sometimes severe persistent side effect of breast cancer treatment among elderly women with a major impact on health‐related quality of life. Chemotherapy regimens without taxane could therefore be a valid option in elderly patients with neurotoxicity risk factors.

show abstract

Delayed Recovery and Increased Severity of Paclitaxel-Induced Peripheral Neuropathy in Patients With Diabetes

Cited by 27 publications

References 0 publications

Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy

Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy

Chemotherapy-induced peripheral neuropathy: Current status and progress

Persistent taxane‐induced neuropathy in elderly patients treated for localized breast cancer

Contact Info

Product

Resources

About